AKABY — Recent News Coverage

All news mentioning AKABY in ESEN's AI-graded feed

News stories with AKABY as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on AKABY. See /coverage/AKABY for the 30-day aggregate.

3 articles Updated: 2026-09-11 08:11 UTC Filter: Ticker: $AKABY
MANILATIMES.NET · 2026-08-14 NEUTRAL BULLISH CORR0.52

ALK’s tree pollen and house dust mite tablets now recommended by NICE for paediatric treatment in the UK health system

$AKABY
◈ ESEN AI
ALK's immunotherapy tablets have received formal NICE recommendation for pediatric use in the UK, expanding their addressable market within the NHS. The approval covers ITULAZAX® (birch pollen, ages 5–17) and ACARIZAX® …
MANILATIMES.NET · 2026-08-13 LOW NEUTRAL CORR0.15

Invitation to the presentation of ALK’s first six months (Q2) 2026 results on Thursday, 20 August 2026

$AKABY $AKBLF
◈ ESEN AI
ALK (trading as AKABY and AKBLF on US exchanges) has announced a scheduled presentation of its H1 2026 financial results for Thursday, 20 August 2026. This is a routine corporate disclosure event typical of publicly lis…
MANILATIMES.NET · 2026-08-05 NEUTRAL BULLISH CORR0.35

Market launch of the nasal adrenaline spray, neffy®, for treatment of adults and children with severe allergies in Canada

$AKABY
◈ ESEN AI
ALK-Ábelo announced the Canadian market launch of neffy®, a first-in-class nasal adrenaline spray for emergency anaphylaxis treatment. Approval from Health Canada in April 2026 preceded this commercial milestone, markin…
EXPLORE OTHER FILTERS